Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Enhancing glioblastoma virotherapy with a bioluminescent Zika virus NS5 sensor and integrated gene circuit

Award Number: R16AI201138
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2026
PERIOD OF PERFORMANCE END DATE: 07/31/2030

Group Awards By:

View Award Description

Enhancing glioblastoma virotherapy with a bioluminescent Zika virus NS5 sensor and integrated gene circuit - ABSTRACT Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, with a median survival of only 15–18 months even with therapy. The poor prognosis reflects the tumor's rapid growth, cellular heterogeneity, and resistance to current treatments. Oncolytic virotherapy has emerged as a promising adjunct, and Zika virus (ZIKV) has unique potential given its natural tropism for glioblastoma stem-like cells. While attenuated ZIKV strains have shown preclinical efficacy in reducing tumor burden, challenges remain regarding safety, incomplete tumor clearance, and limited control over viral replication. To address these limitations, we propose to develop a novel optogenetic gene circuit, BiViSTA (Bioluminescent Viral Sensor and Transcriptional Activator), that detects ZIKV infection and couples it to therapeutic gene expression. BiViSTA leverages a split- luciferase sensor that reconstitutes upon ZIKV NS5 protein binding, producing bioluminescence that activates a light-sensitive transcription factor to drive pro-apoptotic or immunogenic transgenes. This approach uniquely links viral infection to targeted tumor cell destruction, creating a self-amplifying and tumor-restricted therapeutic system. We will pursue three Specific Aims: Aim 1 will engineer and optimize BiViSTA constructs responsive to ZIKV NS5 and validate their function in permissive human cell lines. Aim 2 will integrate BiViSTA into 2-D and 3-D GBM culture models to test selective induction of pro-apoptotic genes and assess enhanced ZIKV-mediated killing. Aim 3 will evaluate tumor-specific activation and therapeutic efficacy in an orthotopic xenograft mouse model of GBM, including rigorous safety assessments. Our multidisciplinary team combines expertise in synthetic biology, neuro-oncology, and viral pathogenesis, supported by strong preliminary data demonstrating a “plug and play” optogenetic system. The proposed work is highly innovative as no existing technology dynamically couples virus infection to therapeutic gene expression in real time. Successful completion will open the door to a transformative strategy that will improve the safety and efficacy of oncolytic virotherapy for GBM that can integrate nonpathogenic ZIKV pseudovirions. Beyond GBM, BiViSTA represents a broadly adaptable platform for treating virus-associated cancers and for dynamically controlling gene expression in basic and translational research.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $144,641 )
2026	2026	CENTRAL MICHIGAN UNIVERSITY	1200 S FRANKLIN ST	MOUNT PLEASANT	MI	48859	ISABELLA	USA	Allergy and Infectious Diseases Research	000	1	8/1/2026	NEW	$144,641
														Subtotal = $144,641

Grand Total All Awards = $144,641

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Enhancing glioblastoma virotherapy with a bioluminescent Zika virus NS5 sensor and integrated gene circuit

Award Number: R16AI201138

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2026

PERIOD OF PERFORMANCE END DATE: 07/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer